Physician profile

David D Vineyard

Obstetrics & Gynecology · Amarillo, TX

NPI 1952360802

$1,150.19

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$135.73

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Fujirebio Diagnostics, Incorporated $724.94 2022
Abbvie INC. $220.93 2020-2023 Lo Loestrin Fe
Coopersurgical, INC. $86.19 2023-2024 Summit Doppler, Advincula Delineator Uterine Manipulator
Daiichi Sankyo INC. $48.24 2021-2022
Bayer Healthcare Pharmaceuticals INC. $24.61 2021
Baudax Bio INC. $23.01 2022
Astellas Pharma US INC $22.27 2024 Veozah

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David D Vineyard

$1,150.19

in general payments reported 2019-2025

Years
2020-2024
Top company
Fujirebio Diagnostics, Incorporated

https://glasscript.com/doctor/960069/david-d-vineyard

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.